Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-22T23:50:18.642Z Has data issue: false hasContentIssue false
  • English
  • Français

The Welfare Cost of Vaccine Misallocation, Delays and Nationalism

Published online by Cambridge University Press:  09 June 2021

Christian Gollier
Christian Gollier*
Affiliation:
Toulouse School of Economics, University of Toulouse-Capitole, Toulouse, France
*
e-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

I calibrate an eco-epidemiological age-structured Susceptible-Infected-Recovered (SIR) model of the B.1.1.7 covid variant on the eve of the vaccination campaign in France, under a stop-and-go lockdown policy. Three-quarters of the welfare benefit of the vaccine can be achieved with a speed of 100,000 full vaccination per day. A 1-week delay in the vaccination campaign raises the death toll by approximately 2500, and it reduces wealth by 8 billion euros. Because of the large heterogeneity of the rates of hospitalization and mortality across age classes, it is critically important for the number of lives saved and for the economy to vaccinate older people first. Any departure from this policy has a welfare cost. Prioritizing the allocation of vaccines to the most vulnerable people save 70,000 seniors, but it also increases the death toll of younger people by 14,000. Vaccine nationalism is modeled by assuming two identical Frances, one with a vaccine production capacity and the other without it. If the production country vaccinates its entire population before exporting to the other, the global death toll would be increased by 20 %. I also measure the welfare impact of the strong French anti-vax movement, and of the prohibition of an immunity passport.

Keywords

anti-vaxxerCovidcovid immunity passportpandemicvaccine

JEL classification

I18: Government Policy • Regulation • Public Health
Type
Article
Information
Journal of Benefit-Cost Analysis , Volume 12 , Issue 2 , Summer 2021 , pp. 199 - 226
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the Society for Benefit-Cost Analysis

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Acemoglu, D., Chernozhukov, V., Werning, I., and Whinston, M.. 2020. “A Multi-Risk SIR Model with Optimally Targeted Lockdown.” NBER Working Paper no. 27102.Google Scholar
Béraud, G., et al. 2015. “The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases.” PLoS ONE, 10, 1–22.CrossRefGoogle ScholarPubMed
Challen, R., Brooks-Pollock, E., Read, J. M., Dyson L, L., Tsaneva-Atanasova, K., and Danon, L.. 2021. “Risk of Mortality in Patients Infected with SARS-CoV-2 Variant of Concern 202012/1: Matched Cohort Study.” The British Medical Journal, 372(372): n579.Google ScholarPubMed
Clarke, P. M., Roope, L. S. J., Loewen, P., Bonnefon, J.-F., Melegaro, A., Friedman, J., Violato, M., Barnett, A., and Duch, R.. 2021. “Public Opinion on Global Rollout of COVID-19 Vaccines.” mimeo, Toulouse School of Economics.CrossRefGoogle Scholar
Drèze, J. 1962. “L’utilité Sociale D’une vie Humaine.” Revue Francaise de Recherche Opérationnelle, 23: 93–118.Google Scholar
Duch, R., et al. 2021. “Who Should be First in Line for the COVID-19 Vaccine? Surveys in 13 Countries of Public’s Preferences for Prioritisation.” medRxiv 2021.01.31.21250866.CrossRefGoogle Scholar
Favero, C., Ichino, A., and Rustichini, A.. 2020. Restarting the Economy While Saving Lives under Covid-19. Milan: WP Bocconi University.CrossRefGoogle Scholar
Fischer, C. 2020. “External Costs and Benefits of Policies to Address COVID-19.” mimeo.Google Scholar
Gollier, C. 2020a. “If Herd Immunity is the Objective, On Whom Should it be Built?” Environmental and Resource Economics 76: 671–683. Prepublished in Covid Economics, 16: 98–114.CrossRefGoogle Scholar
Gollier, C. 2020b. “Pandemic Economics: Optimal Dynamic Confinement under Uncertainty and Learning.” Geneva Risk and Insurance Review, 45: 80–93. Prepublished in Covid Economics, 34: 1–14.CrossRefGoogle Scholar
Gollier, C. 2020c. “Cost-Benefit Analysis of Age-Specific Deconfinement Strategies.” Journal of Public Economic Theory, 22: 1746–1771. Prepublished in Covid Economics, 24: 1–31.CrossRefGoogle Scholar
Hafner, M., Yerushalmi, E., Fays, C., Dufresne, E., and Van Stolk, C.. 2020. COVID-19 and the Cost of Vaccine Nationalism. Santa Monica, CA: RAND Corporation.CrossRefGoogle Scholar
He, X., et al. 2020. “Temporal Dynamics in Viral Shedding and Transmissibility of COVID-19.” Nature Medicine, 26: 672–675. https://doi.org/10.1038/s41591-020-0869-5.CrossRefGoogle ScholarPubMed
Jones-Lee, M. 1974. “The Value of Changes in the Probability of Death and Injury.” Journal of Political Economy, 82: 835–849.CrossRefGoogle Scholar
Kermack, W. O., and McKendrick, A. G.. 1927. “A Contribution to the Mathematical Theory of Epidemics.” Proceedings of the Royal Society, 115: 700–721.Google Scholar
Lapidus, N., Paireau, J., Levy-Bruhl, D., de Lamballerie, X., Severi, G., Touvier, M., Zins, M., Cauchemez, S., and Carrat, F.. 2021. “Do not Neglect SARS-CoV-2 Hospitalization and Fatality Risks in the Middle-Aged Adult Population.” Infectious Diseases Now, 51(4):380–382.CrossRefGoogle ScholarPubMed
Mullard, A. 2020. “How COVID Vaccines are Being Divvied up Around the World.” Nature. 2020 Nov 30. doi: 10.1038/d41586-020-03370-6.CrossRefGoogle Scholar
Murphy, K. M., and Topel, R. H.. 2006. “The Value of Health and Longevity.” Journal of Political Economy, 114: 871–904.CrossRefGoogle Scholar
Quinet, E. 2013. L’évaluation Socioéconomique des Investissements Publics. Paris: Commissariat Général à la Stratégie et à la Prospective.Google Scholar
Saltje, H., et al. 2020. “Estimating the Burden of SARS-CoV-2 in France.” pasteur-02548181.Google Scholar
Schelling, T. 1968. “The Life you Save may be Your Own.” in Chase, S.B. (Ed.) Problems in Public Expenditure Analysis. 127–162. Washington, DC: The Brookings Institution.Google Scholar
Shepard, D. S., and Zeckhauser, R. J.. 1984. “Survival Versus Consumption.” Management Science, 30: 423–439.CrossRefGoogle Scholar
US-EPA. 2010. “Valuing Mortality Risk Reductions for Environmental Policy: A White Paper.” SAB-EEAC Review Report.Google Scholar
Viscusi, W. K. 2009. “The Devaluation of Life.” Regulation & Governance, 3: 103–127.CrossRefGoogle Scholar
Volz, E., et al. 2020. “Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from Linking Epidemiological and Genetic Data.” medRxiv 2020.12.30.20249034.Google Scholar
WHO. 2020a. WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19. Geneva: World Health Organization.Google Scholar
WHO. 2020b. WHO SAGE Roadmap for Prioritizing Uses of Covid-19 Vaccines in the Context of Limited Supply. Geneva: World Health Organization.Google Scholar
Wilder, B., Charpignon, M., Killian, J., Han-Ching, O., Mate, A., Jabbari, S., Perrault, A., Desai, A., Tambe, M. and Majumder, M.. 2020. “The Role of Age Distribution and Family Structure on COVID-19 Dynamics: A Preliminary Modeling Assessment for Hubei and Lombardy.” mimeo.CrossRefGoogle Scholar